Biology subjects

Loi, G. W. Z.

Publications and source records attributed to Loi, G. W. Z..

3 recordsLinked to original sources

bioRxiv2024

Lysosome-acidifying nanoparticles rescue A30P α-synuclein induced neuronal death in cellular and Drosophila models of Parkinson's disease

Parkinsons disease (PD) is an age-related neurodegenerative disease characterized by histopathological hallmarks of Lewy bodies formed by accumulation of -synuclein (Syn) and progressive loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain, with clinical symptoms of motor deficits. Toxic protein accumulation of Syn in PD is associated with autolysosomal acidification dysfunction that contributes to defective autophagy-lysosomal degradation system. While lysosome-acidifying nanoparticles have been applied as therapeutics to ameliorate dopaminergic neurodegeneration in neurotoxin mediated or Syn aggregates induced mouse model of sporadic PD, lysosome-targeted approach has not yet been applied in synucleinopathy models of familial PD. Here, we report the first application of the new poly(ethylene tetrafluorosuccinate-co-succinate) (PEFSU)-based acidic nanoparticles (AcNPs) in A30P Syn overexpressing SH-SY5Y cells and Drosophila models of PD. In the cellular model, we showed that AcNPs restore lysosomal acidification, promote autophagic clearance of Syn, improve mitochondrial turnover and function, and rescue A30P Syn induced death in SH-SY5Y cells. In the Drosophila model, we demonstrated that AcNPs enhance clearance of Syn and rescue dopaminergic neuronal loss in fly brains and improve their locomotor activity. Our results highlight AcNPs as a new class of lysosome-acidifying therapeutic for treatment of PD and other proteinopathies in general.

neuroscience↗

bioRxiv2023

Defective lysosomal acidification contributes to TNFR1 mediated neuronal necroptosis in Alzheimer's disease

Background: Tumor necrosis factor (TNF) receptor 1 (TNFR1) signaling mediates neuronal necroptosis in Alzheimer's disease (AD). Interaction of TNFR1 signaling axis with autolysosomal pathway and the accumulation of necrosome molecules in impaired lysosomes have been shown to lead to necroptotic neuronal death. This has been attributed to the terminal failure of the autophagic process, primarily due to lysosomal degradation dysfunction. Being the final and determining step of the autolysosomal pathway, lysosomes with sufficient acidification as maintained by functional vacuolar (H+)-ATPase (V-ATPase) are required to achieve complete autophagic degradation of toxic cellular components. Here, we aim to investigate the role of defective lysosomal acidification in mediating TNFR1 induced neuronal necroptosis in AD. Methods: Neuropathological analysis of human post-mortem AD brains was performed to examine the correlation between TNFR1 induced neuronal necroptosis and autolysosomal dysfunction. Specifically, we probed for the level of V-ATPase subunits in AD brains to determine the extent of lysosomal acidification and function. Cell-based assays were conducted to understand the effect of TNFR1 activation in driving lysosomal acidification defect, proteolytic function, membrane integrity, autophagic impairment, mitochondrial dysfunction, and neuronal death in SH-SY5Y neuroblastoma cells. Furthermore, we applied lysosome-acidifying nanoparticles (AcNPs) to determine whether restoration of lysosomal acidification can rescue neuronal necroptosis in both TNF-treated SH-SY5Y cells and APPNL-G-F knock-in mouse model of AD. Results: We found that TNFR1 activated neuronal necroptosis correlated with autolysosomal dysfunction as characterized by downregulation of V-ATPase subunits and accumulation of autophagy receptor p62 in human AD brains. In cell culture, we showed for the first time that lysosomal acidification is only impaired in cells treated with TNF and not with other cytokines, contributing to inhibition of autophagic degradation in SH-SY5Y cells. TNF also disrupted lysosomal trafficking and membrane dynamics and induced lysosomal membrane permeabilization, followed by impaired autophagic clearance, defective mitochondrial turnover, reduced mitochondrial function, and neuronal death. Importantly, we demonstrated that AcNPs restored lysosomal, autophagic, and mitochondrial function, improved lysosomal membrane homeostasis, and rescued neuronal necroptosis in both TNF-treated SH-SY5Y cells and APPNL-G-F mice.

neuroscience↗

bioRxiv2023

Acidic nanoparticles restore lysosomal acidification and rescue metabolic dysfunction in pancreatic β-cells under lipotoxic condition

Type 2 diabetes (T2D), a prevalent metabolic disorder lacking effective treatments, is associated with lysosomal acidification dysfunction as well as autophagic and mitochondrial impairments. Here, we report a series of biodegradable poly(butylene tetrafluorosuccinate-co-succinate) (PBFSU) polyesters, comprising an 1,4-butanediol linker and varying ratios of tetrafluorosuccinic acid (TFSA) and succinic acid as components, to engineer new lysosome acidifying nanoparticles (NPs). Notably, TFSA NPs, which composed entirely of TFSA, exhibit the strongest degradation capability and superior acidifying property. We further reveal significant downregulation of lysosomal vacuolar (H+)-ATPase (V-ATPase) subunits, which are responsible for maintaining lysosomal acidification, in human T2D pancreatic islets and INS-1 {beta}-cells under lipotoxic condition. Treatment of TFSA NPs counteracts lipotoxicity in INS-1 {beta}-cells by restoring lysosomal acidification, autophagic function, and mitochondrial activity, along with promoting glucose-stimulated insulin secretion. Administration of TFSA NPs to high-fat diet T2D mice improves glucose clearance and reduces insulin resistance. These findings highlight the therapeutic potential of lysosome acidifying TFSA NPs for T2D. Graphical Table of Contents O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=168 SRC="FIGDIR/small/548395v2_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@faec9eorg.highwire.dtl.DTLVardef@1c4a6b5org.highwire.dtl.DTLVardef@19cd6ceorg.highwire.dtl.DTLVardef@1da9a4b_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗